SUPPRESSION OF THE GROWTH HORMONE/INSULIN-LIKE GROWTH FACTOR-1 (GH/IGF-1) AXI

生长激素/胰岛素样生长因子-1 (GH/IGF-1) AXI 的抑制

• 批准号: 7375806
• 负责人: Joan Marie Bathon
• 金额: $ 0.18万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375806
• 关键词: SUPPRESSION; GROWTH; HORMONE; INSULIN; LIKE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a 6-month, open label, pilot study in pre-menopausal women with rheumatoid arthritis (RA) of less than 3 years duration to be conducted at the General Clinical Research Center (GCRC) of the Johns Hopkins Bayview Medical Center, Baltimore, MD and the Clinical Center of National Institutes of Health. This investigation will explore the possible impact of systematically released inflammatory cytokines on suppression of the GH/IGF-1 axis, and the relationships of altered endocrine-immune function with body composition, metabolic and vascular functions thought to be associated with RA-related sarcopenia, osteopenia, and increased risk of cardiovascular disease. In phase I of the study, we shall admit RA patients and control subjects to the Clinical Center for a 36 hour period for assessments of the GH/IGF-1 axis, cytokines, body composition, endocrine-metabolic and cardiovascular functions, and quality of life. In Phase II of the study, we shall re-evaluate the above outcome measures after six months of treatment of the RA patients with Etanercept, a soluble p75 TNF receptor molecule, which has recently been approved by the FDA for the treatment of patients with early RA.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项为期6个月，开放标签，绝经前女性类风湿关节炎（RA）持续时间少于3年的试点研究，将在马里兰州巴尔的摩市约翰霍普金斯湾景医学中心的普通临床研究中心（GCRC）和国立卫生研究院临床中心进行。本研究将探讨系统释放的炎性细胞因子对抑制GH/IGF-1轴的可能影响，以及内分泌免疫功能改变与机体组成、代谢和血管功能的关系，这些被认为与ra相关的肌肉减少症、骨质减少症和心血管疾病风险增加有关。在研究的第一阶段，我们将把RA患者和对照组纳入临床中心，进行36小时的GH/IGF-1轴、细胞因子、身体成分、内分泌代谢和心血管功能以及生活质量的评估。在II期研究中，我们将在使用依那西普治疗RA患者6个月后重新评估上述结果。依那西普是一种可溶性p75 TNF受体分子，最近已被FDA批准用于治疗早期RA患者。